These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 15117934)

  • 1. Clinical efficacy of ketolides in the treatment of respiratory tract infections.
    Reinert RR
    J Antimicrob Chemother; 2004 Jun; 53(6):918-27. PubMed ID: 15117934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ketolides: a critical review.
    Zhanel GG; Walters M; Noreddin A; Vercaigne LM; Wierzbowski A; Embil JM; Gin AS; Douthwaite S; Hoban DJ
    Drugs; 2002; 62(12):1771-804. PubMed ID: 12149046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketolides in the treatment of respiratory infections.
    Zhanel GG; Hoban DJ
    Expert Opin Pharmacother; 2002 Mar; 3(3):277-97. PubMed ID: 11866679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
    Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
    J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.
    Zhanel GG; Hisanaga T; Nichol K; Wierzbowski A; Hoban DJ
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):297-321. PubMed ID: 14661991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telithromycin: an oral ketolide for respiratory infections.
    Bearden DT; Neuhauser MM; Garey KW
    Pharmacotherapy; 2001 Oct; 21(10):1204-22. PubMed ID: 11601667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections.
    Hammerschlag MR; Sharma R
    Expert Opin Investig Drugs; 2008 Mar; 17(3):387-400. PubMed ID: 18321237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Telithromycin].
    Benes J
    Klin Mikrobiol Infekc Lek; 2004 Feb; 10(1):16-21. PubMed ID: 15100978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.
    Low DE; Brown S; Felmingham D
    Clin Microbiol Infect; 2004 Jan; 10(1):27-36. PubMed ID: 14706083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ketolides and oxazolidinones. Mechanisms of action and antibacterial spectrum].
    Muller-Serieys C
    Presse Med; 2000 Dec; 29(37):2061-4. PubMed ID: 11155736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J
    Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical management of respiratory tract infections in the community: experience with telithromycin.
    Quintiliani R
    Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.
    Lonks JR; Goldmann DA
    Clin Infect Dis; 2005 Jun; 40(11):1657-64. PubMed ID: 15889365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of macrolides and ketolides: focus on respiratory tract infections.
    Zhanel GG; Dueck M; Hoban DJ; Vercaigne LM; Embil JM; Gin AS; Karlowsky JA
    Drugs; 2001; 61(4):443-98. PubMed ID: 11324679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
    Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telithromycin. Aventis Pharma.
    Johnson AP
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1691-701. PubMed ID: 11892930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
    Carter PL
    Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae.
    Champney WS; Mentens N; Zurawick K
    Curr Microbiol; 2004 Oct; 49(4):239-47. PubMed ID: 15386111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections.
    Van Bambeke F; Harms JM; Van Laethem Y; Tulkens PM
    Expert Opin Pharmacother; 2008 Feb; 9(2):267-83. PubMed ID: 18201149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.